These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 31529406)

  • 21. Clinical pharmacokinetics, pharmacodynamics, safety and tolerability of darexaban, an oral direct factor Xa inhibitor, in healthy Caucasian and Japanese subjects.
    Kadokura T; Kashiwa M; Groenendaal D; Heeringa M; Mol R; Verheggen F; Garcia-Hernandez A; Onkels H
    Biopharm Drug Dispos; 2013 Nov; 34(8):431-41. PubMed ID: 23929659
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics, pharmacodynamics, and tolerability of a generic formulation of exenatide: a randomized, open-label, single- and multiple-dose study in healthy Chinese volunteers.
    Shi S; Liu Y; Li Z; Wu J; Zhou X; Zeng F
    Arzneimittelforschung; 2012 Feb; 62(2):75-82. PubMed ID: 22344551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics, Safety, and Tolerability of Tenapanor in Healthy Chinese and Caucasian Volunteers: A Randomized, Open-Label, Single-Center, Placebo-Controlled Phase 1 Study.
    Yuan G; Chen Y; Li L; Wang X; Wei G; Zeng J; Hui AM; Jiang Y; Zhao H; Diao L; Zhou Y; Xiao Y; Chen M
    Int J Clin Pract; 2024; 2024():1386980. PubMed ID: 38481823
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and safety of sirukumab following a single subcutaneous administration to healthy Japanese and Caucasian subjects.
    Zhuang Y; Xu Z; de Vries DE; Wang Q; Shishido A; Comisar C; Ford JA; Keen M; Achira M; Tsukamoto Y; Petty KJ; Davis HM; Zhou H
    Int J Clin Pharmacol Ther; 2013 Mar; 51(3):187-99. PubMed ID: 23357841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics, pharmacodynamics, and safety of asundexian in healthy Chinese and Japanese volunteers, and comparison with Caucasian data.
    Chen H; Hashizume K; Kanefendt F; Brase C; Schmitz S; Liu T
    Clin Transl Sci; 2024 Aug; 17(8):e13895. PubMed ID: 39082898
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the pharmacokinetics of subcutaneous ustekinumab between Chinese and non-Chinese healthy male subjects across two Phase 1 studies.
    Zhu Y; Wang Q; Frederick B; Bouman-Thio E; Marini JC; Keen M; Petty KJ; Davis HM; Zhou H
    Clin Drug Investig; 2013 Apr; 33(4):291-301. PubMed ID: 23512638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy, safety and pharmacokinetics of indacaterol in Caucasian and Japanese patients with chronic obstructive pulmonary disease: a comparison of data from two randomized, placebo-controlled studies.
    Hosoe M; Woessner R; Matsushima S; Lawrence D; Kramer B
    Clin Drug Investig; 2011; 31(4):247-55. PubMed ID: 21184620
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
    O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
    Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics, Pharmacodynamics, Safety, and Clinical Activity of Multiple Doses of RCT-18 in Chinese Patients With Systemic Lupus Erythematosus.
    Zhao Q; Chen X; Hou Y; Jiang J; Zhong W; Yao X; Wang W; Li L; Fang J; Zhang F; Hu P
    J Clin Pharmacol; 2016 Aug; 56(8):948-59. PubMed ID: 26634642
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Similarity of insulin detemir pharmacokinetics, safety, and tolerability profiles in healthy caucasian and Japanese american subjects.
    Jhee SS; Lyness WH; Rojas PB; Leibowitz MT; Zarotsky V; Jacobsen LV
    J Clin Pharmacol; 2004 Mar; 44(3):258-64. PubMed ID: 14973299
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and tolerability of serelaxin, a recombinant human relaxin-2 in development for the treatment of acute heart failure, in healthy Japanese volunteers and a comparison of pharmacokinetics and pharmacodynamics in healthy Japanese and Caucasian populations.
    Dahlke M; Ng D; Yamaguchi M; Machineni S; Berger S; Canadi J; Rajman I; Lloyd P; Pang Y
    J Clin Pharmacol; 2015 Apr; 55(4):415-22. PubMed ID: 25408331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-962212, a direct, reversible, small molecule factor XIa inhibitor in non-Japanese and Japanese healthy subjects.
    Perera V; Luettgen JM; Wang Z; Frost CE; Yones C; Russo C; Lee J; Zhao Y; LaCreta FP; Ma X; Knabb RM; Seiffert D; DeSouza M; Mugnier P; Cirincione B; Ueno T; Frost RJA
    Br J Clin Pharmacol; 2018 May; 84(5):876-887. PubMed ID: 29346838
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of atacicept in combination with rituximab for reducing the signs and symptoms of rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled pilot trial.
    van Vollenhoven RF; Wax S; Li Y; Tak PP
    Arthritis Rheumatol; 2015 Nov; 67(11):2828-36. PubMed ID: 26137975
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single-dose pharmacokinetics of the HCV polymerase inhibitor mericitabine in healthy Caucasian and Japanese subjects.
    Washington C; Moreira S; Haznedar J; Goelzer P; Chen YC
    Drug Metab Pharmacokinet; 2014; 29(2):141-7. PubMed ID: 24025983
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety, tolerability, and pharmacokinetics of single- and multiple-ascending doses of olamkicept: Results from randomized, placebo-controlled, first-in-human phase I trials.
    Wagner FD; Schreiber S; Bagger Y; Bruzelius K; Falahati A; Sternebring O; Ravi A; Pinton P
    Clin Transl Sci; 2024 May; 17(5):e13832. PubMed ID: 38769747
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial.
    Kappos L; Hartung HP; Freedman MS; Boyko A; Radü EW; Mikol DD; Lamarine M; Hyvert Y; Freudensprung U; Plitz T; van Beek J;
    Lancet Neurol; 2014 Apr; 13(4):353-63. PubMed ID: 24613349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of Tramadol and Celecoxib in Japanese and Caucasian Subjects Following Administration of Co-Crystal of Tramadol-Celecoxib (CTC): A Randomised, Open-Label Study.
    Dooner H; Mundin G; Mersmann S; Bennett C; Lorch U; Encabo M; Escriche M; Encina G; Smith K
    Eur J Drug Metab Pharmacokinet; 2019 Feb; 44(1):63-75. PubMed ID: 29956215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Phase 1, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Subcutaneous Tezepelumab in Healthy Japanese Men.
    Sakamoto K; Matsuki S; Irie S; Uchida N; Hayashi N; Horiuchi M; Ren S
    Clin Pharmacol Drug Dev; 2020 Oct; 9(7):833-840. PubMed ID: 31960624
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
    Ford J; Lawson M; Fowler D; Maruyama N; Mito S; Tomiyasu K; Kinoshita S; Suzuki C; Kawaguchi A; Round P; Boyce M; Warrington S; Weber W; van Deventer S; Kastelein JJ
    Br J Clin Pharmacol; 2014 Sep; 78(3):498-508. PubMed ID: 24628035
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Atacicept as an investigated therapy for rheumatoid arthritis.
    Richez C; Truchetet ME; Schaeverbeke T; Bannwarth B
    Expert Opin Investig Drugs; 2014 Sep; 23(9):1285-94. PubMed ID: 25078871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.